文献速递胸部肿瘤放疗

定量CT肿瘤体积特征对局限期小细胞肺癌放疗后结局的影响

The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2020-01-14

该回顾性队列纳入105例2000至2013年接受放化疗的局限期小细胞肺癌患者,比较基于CT的肿瘤体积测量与IASLC TNM分期对结局的预测价值。中位随访21.3个月,2年局部区域复发率38%、远处转移率52%、总生存率47%。单因素和多因素分析显示3D最大肿瘤直径与所有结局显著相关,而UICC T和N分期与任何临床结局均无关。

要点

  • 3D最大肿瘤直径与LRR、野外LRR、DM、任何进展和OS均显著相关(HR 1.10)。
  • UICC T和N分期与任何临床结局均无关,仅总体分期与野外LRR相关。
  • 定量CT体积特征或优于TNM分期用于LS-SCLC风险分层。

核心结论

  • 对LS-SCLC,基于CT的定量肿瘤体积测量与放化疗后结局显著相关,可能比TNM分期更好地预测结局。

研究设计与样本

  • 回顾性队列纳入105例2000至2013年接受放化疗的LS-SCLC患者,按UICC第8版TNM分期,从放疗计划CT提取肿瘤体积和直径,用单因素和多因素模型分析其与OS、LRR、野外LRR、任何进展和DM的关系。

主要发现

  • 中位随访21.3个月,2年LRR为38%、野外LRR为31%、DM为52%、任何进展为62%、OS为47%,中位生存16.5个月。
  • 单因素分析中UICC T分期和N分期与任何临床结局均无关,UICC总体分期仅与野外LRR统计学相关。
  • 3D最大肿瘤直径与LRR(HR 1.10,p=0.003)、野外LRR(HR 1.10,p=0.007)、DM(HR 1.10,p=0.02)、任何进展(HR 1.10,p=0.008)和OS(HR 1.10,p=0.03)显著相关。
  • 多因素分析中该影像特征仍与所有结局显著相关。

临床怎么用

  • 在LS-SCLC放化疗前可利用放疗计划CT测量3D最大肿瘤直径辅助风险分层。
  • TNM分期对LS-SCLC结局的预测价值有限,可结合定量CT体积特征综合评估。

局限性

  • 回顾性单中心队列,样本量105例,中位随访21.3个月,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited stage small cell lung cancer (LS-SCLC) has a poor prognosis. Additional prognostic markers are needed for risk-stratification and treatment intensification. This study compares quantitative CT-based volumetric tumor measurements versus International Association for the Study of Lung Cancer (IASLC) TNM staging to predict outcomes. MATERIALS & METHODS: A cohort of 105 patients diagnosed with LS-SCLC and treated with chemoradiation (CRT) from 2000 to 2013 were analyzed retrospectively. Patients were staged by the Union for International Cancer Control (UICC) TNM Classification, 8th edition. Tumor volumes and diameters were extracted from radiation planning CT imaging. Univariable and multivariable models were used to analyze relationships between CT features and overall survival (OS), locoregional recurrence (LRR), in-field LRR, any progression, and distant metastasis (DM). RESULTS: Median follow-up was 21.3 months. Two-year outcomes were as follows: 38% LRR, 31% in-field LRR, 52% DM, 62% any progression, and 47% OS (median survival 16.5 months). On univariable analysis, UICC T-stage and N-stage were not associated with any clinical outcome. UICC overall stage was only statistically associated with in-field LRR. One imaging feature (3D maximum tumor diameter) was found to be significantly associated with LRR (HR 1.10, p = 0.003), in-field LRR (HR 1.10, p = 0.007), DM (HR 1.10, p = 0.02), any progression (HR 1.10, p = 0.008), and OS (HR 1.10, p = 0.03). On multivariable analysis, this feature remained significantly associated with all outcomes. CONCLUSION: For LS-SCLC, quantitative CT-based volumetric tumor measurements were significantly associated with outcomes after CRT and may be better predictors of outcome than TNM stage.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kamran SC, Coroller T, Milani N, et al. The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer. Radiat Oncol. 2020. PMID: 31937336. doi:10.1186/s13014-020-1460-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。